WALD — Waldencast plc

Waldencast (WALD) Q1 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Revenue: $65.4 million, a decline of 4.1% year-over-year.
• Adjusted Gross Profit Margin: 76.4%, up 10 basis points year-over-year.
• Adjusted EBITDA: $4.4 million, representing a margin of 6.7%.
• Milk Makeup Revenue: Declined 15.1%, with a strong domestic performance offset by international challenges.
• Obagi Medical Revenue: Increased 7.1% to $36.2 million, impacted by out-of-stock issues.
• Cash Position: $10.8 million, with an additional $22.5 million available on a revolving credit facility.
• Net Debt: Increased to $172.1 million from $154.2 million at the end of 2024.

2. Strategic Updates and Business Highlights:

• Brand Performance:
  • Milk Makeup: Launched Hydro Grip Gel Skin Tint, which sold out quickly and contributed to high single-digit growth in US retail sales.
  • Obagi Medical: Focused on supply chain transformation to improve operational efficiency and address out-of-stock issues.
• Distribution Expansion: Milk Makeup successfully launched in 600 Ulta Beauty stores, with plans for further expansion based on initial success.
• Innovation Pipeline: Continued focus on launching new products and expanding into high-replenishment categories.

3. Forward Guidance and Outlook:

• Revenue Growth Target: Mid-teens for fiscal 2025.
• Adjusted EBITDA Margin Target: Mid to high-teens.
• Key Growth Drivers: Expected improvements in product availability, continued innovation, and expansion of digital and retail channels.

4. Challenges and Points of Concern:

• Declining Revenue: Overall revenue decline attributed to tough comparisons from previous year and challenges in the beauty market.
• Supply Chain Issues: Ongoing restructuring has caused out-of-stock situations, particularly for Obagi Medical.
• Macroeconomic Pressures: Anticipated pressure from softer consumer sentiment and spending, with potential impacts from tariffs.
• International Performance: Milk Makeup's international sales were negatively affected by tough year-over-year comparisons and inventory adjustments by retail partners.

5. Notable Q&A Insights:

• Supply Chain Restructuring: Management emphasized the need for improved flexibility and responsiveness in the supply chain to meet demand.
• Physician Channel Performance: No significant slowdown in the physician channel was noted; challenges were more related to the absence of prior year tailwinds from Amazon.
• Pricing Strategy: Management indicated that any potential tariff impacts could be managed with low to mid-single-digit price increases.
• Marketing Investments: Increased focus on consumer outreach for Obagi and top-of-funnel advertising for Milk Makeup to drive brand awareness and sales.

Overall, while Waldencast faced challenges in Q1 2025, management remains optimistic about future growth driven by strategic initiatives and brand strength.